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Vav and Vav2 are members of the Dbl family of pro-
teins that act as guanine nucleotide exchange factors
(GEFs) for Rho family proteins. Whereas Vav expression
is restricted to cells of hematopoietic origin, Vav2 is
widely expressed. Although Vav and Vav2 share highly
related structural similarities and high sequence iden-
tity in their Dbl homology domains, it has been reported
that they are active GEFs with distinct substrate speci-
ficities toward Rho family members. Whereas Vav dis-
played GEF activity for Rac1, Cdc42, RhoA, and RhoG,
Vav2 was reported to exhibit GEF activity for RhoA,
RhoB, and RhoG but not for Rac1 or Cdc42. Consistent
with their distinct substrate targets, it was found that
constitutively activated versions of Vav and Vav2
caused distinct transformed phenotypes when ex-
pressed in NIH 3T3 cells. In contrast to the previous
findings, we found that Vav2 can act as a potent GEF for
Cdc42, Rac1, and RhoA in vitro. Furthermore, we found
that NH2-terminally truncated and activated Vav and
Vav2 caused indistinguishable transforming actions in
NIH 3T3 cells that required Cdc42, Rac1, and RhoA func-
tion. In addition, like Vav and Rac1, we found that Vav2
activated the Jun NH2-terminal kinase cascade and also
caused the formation of lamellipodia and membrane ruf-
fles in NIH 3T3 cells. Finally, Vav2-transformed NIH 3T3
cells showed up-regulated levels of Rac-GTP. We con-
clude that Vav2 and Vav share overlapping downstream
targets and are activators of multiple Rho family pro-
teins. Therefore, Vav2 may mediate the same cellular
consequences in nonhematopoietic cells as Vav does in
hematopoietic cells.
Dbl family proteins serve as guanine nucleotide exchange
factors (GEFs)1 and activators of specific Rho family small
GTPases (reviewed in Refs. 1 and 2). Rho family proteins func-
tion as GDP/GTP-regulated molecular switches that cycle be-
tween an active GTP-bound state and an inactive GDP-bound
state (reviewed in Refs. 3–5). Whereas Dbl family proteins
stimulate GDP dissociation to promote the formation of the
active GTP-bound protein, Rho family proteins are inactivated
by GTPase-activating proteins (GAPs) that stimulate the in-
trinsic rate of GTP hydrolysis. A wide array of extracellular
stimuli has been shown to promote the activation of Rho family
proteins, most likely through the activation of Dbl family
proteins.
Fourteen mammalian members of the Rho family of proteins
have been identified: RhoA, RhoB, RhoC, RhoD, RhoE, Rnd1/
Rnd6, Rnd2/Rho7, RhoG, Rac1, Rac2, Rac3, Cdc42, TC10, and
TTF (5). Rho family proteins have been shown to regulate actin
cytoskeletal organization, thus influencing cell shape, adhe-
sion, and motility (reviewed in Refs. 3–5). For example, RhoA
promotes the formation of actin stress fibers and focal adhe-
sions, whereas Rac1 promotes the formation of lamellipodia
and membrane ruffling, and Cdc42 causes actin microspike
formation and filopodia development.
Rho family proteins are also activators of signaling pathways
that regulate gene expression and cell growth (3–5). For exam-
ple, Rac1 and Cdc42 but not RhoA activate the Jun NH2-
terminal kinase (JNK) mitogen-activated protein kinase cas-
cade, and JNK in turn phosphorylates and activates the Jun,
ATF-2 and Elk-1 transcription factors (6, 7). RhoA, Rac1, and
Cdc42 are also activators of the NF-kB and serum response
factor transcription factors (8, 9). These transcription factors in
turn regulate genes that promote cell growth. Rho family pro-
teins are also required for progression through the G1 phase of
the cell cycle, in part, by up-regulating the expression of cyclin
D1 (10, 11). Thus, it is not surprising that the aberrant activa-
tion of Rho family proteins can promote cellular transforma-
tion, and the proteins are required for the transforming actions
of Ras and other oncoproteins.
To date, over 30 mammalian Dbl family members have been
identified. All Dbl family proteins share a tandem Dbl homol-
ogy (DH) and pleckstrin homology (PH) domain structure (re-
viewed in Refs. 1 and 2). The DH domain serves as the GTPase
binding and GEF catalytic domain. Whereas some Dbl proteins
show very specific substrate specificity, others show broad sub-
strate specificity. For example, the Dbl family proteins Lsc,
Fdg1, and Tiam1 are specific for RhoA, Cdc42, and Rac1, re-
spectively (12–14). In contrast, Vav has been found to activate
multiple Rho family proteins (Rac1, RhoA, RhoB, RhoG, and
Cdc42) (15–18). Although the structural basis for substrate
specificity of DH domains remains to be delineated, we have
observed that the overall sequence identities of DH domains
does broadly correlate with their GTPase targets (2).
Although PH domains are found in other signaling proteins,
a PH domain is invariantly positioned just COOH-terminal to
the DH domain within Dbl family proteins (1, 2). Thus, the
tandem DH/PH association suggests that these domains may
be functionally interdependent. Presently, it is believed that
the PH domain facilitates the membrane localization of Dbl
family proteins, where their GTPase substrates reside (19, 20).
A second function involves the positive or negative regulation
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of the catalytic function of the DH domain (21–23). Outside the
DH domains, Dbl family members generally share little se-
quence similarity. Because NH2-terminal deletion of sequences
upstream of the DH domain creates transforming versions of
various Dbl family proteins (e.g. Vav, Dbl, and Tiam1), the
NH2-terminal sequences may serve a negative regulatory role
for these proteins.
A majority of Dbl family proteins have been shown to exhibit
transforming potential in NIH 3T3 focus formation assays: Dbl,
Vav, Dbs, Ost, Ect2, Net1, Tim, Lbc, Lsc, Lfc, Tiam1, Trio, and
Fgd1 (1, 2). Several lines of evidence indicate that Dbl family
transformation is the result of their deregulation of Rho
GTPase activity. First, where it has been analyzed, mutation of
the DH domain causes a loss of transforming activity. Second,
Dbl family proteins cause the same changes in actin cytoskel-
etal organization as their small GTPase substrates. Third,
constitutively activated Rho GTPases and Dbl family proteins
cause very similar transformed phenotypes when assayed in
rodent fibroblasts and other cell types. Fourth, Dbl family
members can activate similar signaling pathways as their Rho
GTPase substrates. Thus, the activation of Rho GTPases plays
an important role in Dbl transformation.
Vav and Vav2 are members of the Dbl family of proteins.
These two proteins are highly related showing 63% sequence
similarity and 55% identity (24, 25). In particular, among all
Dbl family proteins, the DH domain of Vav2 shares the strong-
est sequence identity with that of Vav. The transforming ac-
tivity of both Vav and Vav2 can be activated by NH2-terminal
truncation (25, 26). Both proteins also contain the same spec-
trum of COOH-terminal protein-protein or protein-lipid inter-
action motifs. Following the PH domain is a cysteine-rich do-
main and tandem Src homology 3 (SH3) domains split by an
intervening SH2 domain. However, Vav and Vav2 are also
distinct in several ways. First, whereas Vav expression is re-
stricted to hematopoietic cells, Vav2 is expressed ubiquitously.
Second, although Vav has shown GEF activity on RhoA, RhoG,
Rac1, and Cdc42 in vitro (15, 16, 18), Vav2 has recently been
reported to have GEF activity on RhoA, RhoB, and RhoG but
not on Rac1 and Cdc42 in vitro (18). Furthermore, Vav and
Vav2 were also demonstrated to have distinct consequences on
cell morphology and actin organization and caused distinct
transformed phenotypes that correlated with their different
substrate specificity. Thus, it has been proposed that Vav and
Vav2 may be activated by similar upstream stimuli but then
stimulate distinct downstream signaling events and biological
outcomes.
We have evaluated the biochemical and biological properties
of Vav2. In contrast to previous observations, we found that
Vav2 is an activator of RhoA, Rac1, and Cdc42. Similar to Vav,
Vav2 (a DH or DH/PH/CRD fragment) exhibited potent gua-
nine nucleotide exchange activity on RhoA, Rac1, and Cdc42 in
vitro. Consistent with this exchange activity, Vav2 caused a
similar transformed phenotype as Vav when expressed in NIH
3T3 cells. Furthermore, like Vav, Vav2 transforming activity
was impaired by inhibition of RhoA, Rac1, and Cdc42 function.
Like Rac1, Vav2 also induced the formation of lamellipodia and
membrane ruffles in NIH 3T3 cells. Vav2 also stimulated the
activity of the c-Jun transcription factor, a signaling pathway
activated by Rac or Cdc42. Finally, Vav2-transformed NIH 3T3
cells showed a significant increase in the levels of Rac-GTP.
Thus, when taken together, our data suggest that Vav2 can
activate multiple Rho GTPases similar to its related family
member Vav.
EXPERIMENTAL PROCEDURES
Molecular Constructs—The pAX142 mammalian expression plasmid
(20) and pAX142 DN-186 vav have been described previously (27). The
DN-191 Vav2 mutant was generated by polymerase chain reaction
using wild-type full-length Vav2 (pCMV5-vav2; a generous gift from
Dan Broek) as a template. A 59 primer (CA GGT ACC GGC ATG ACT
GAA GAT GAC AAG) containing a KpnI site and seven Vav2 NH2-
terminal residues corresponding to residues 192–198 was used in con-
junction with a 39 primer (CA GGT ACC GGC GTC CAG ATC TGC AGG
AGA) containing a KpnI and a BglII site (the BglII site corresponds to
residue 578 in Vav2) to generate a 1.7-kilobase fragment. This fragment
was digested with KpnI and ligated into a KpnI-digested pCMV5-vav2
plasmid. This plasmid containing the polymerase chain reaction-gener-
ated fragment was then sequenced. The pCMV5-vav2 1 insert frag-
ment was digested with BglII, and the larger vector fragment was
recovered and religated together (pCMV5 DN-191vav2). To compare
DN-186 Vav and DN-191 Vav2 transforming activities, pCMV5
D-191vav2 was digested with KpnI and HindIII, converted to blunt ends
using T4 DNA polymerase (Life Technologies, Inc.), and ligated into the
SmaI site in pAX142.
pZIP-NeoSV(x)1 retrovirus mammalian expression constructs encod-
ing wild-type or dominant negative mutants of RhoA, Rac1, or Cdc42,
and Rho GAP p190 have been described and characterized previously
(28). cDNAs encoding wild-type p190 Rho GAP (29) and C3 transferase
were provided by R. Weinberg and J. Settleman, respectively. pyDF30
WASP-GBD encodes the NH2-terminal sequences of WASP that con-
tains the Cdc42-GBD and WASP-GBD has been shown to function as an
inhibitor of Cdc42 function (provided by M. Symons) (10, 30, 31).
Cell Culture, Transfection, and Transformation Assays—NIH 3T3
cells were maintained in Dulbecco’s modified Eagle medium supple-
mented with 10% bovine calf serum. Transfections were performed
using calcium phosphate co-precipitation in conjunction with glycerol
shock as described previously (32). For each assay, cognate empty
vector was used as a control. For focus formation analyses, transfected
NIH 3T3 cells were maintained in growth medium for 12–14 days. The
cultures were then stained with crystal violet (0.5%), and the number of
foci of transformed cells was then quantitated. To select for NIH 3T3
cells stably expressing constitutively activated Vav2, pAX142 DN191-
Vav2 (1 mg) were co-transfected with the pZIP-NeoSV(x)1 empty plas-
mid (neomycin resistant) and maintained in growth medium supple-
mented with G418 (400 mg/ml). NIH 3T3 cells stably expressing
constitutively activated Vav by transfection of pCTV3 DN-186 Vav and
selection of stably transfected cells were established by isolating drug-
resistant colonies after growth in medium supplemented with hygro-
mycin. Multiple drug resistant colonies (.100) were pooled together to
establish the stable cell lines for use in the various assays described.
Anchorage-independent growth assays were performed as described
previously (32). For immunofluorescence analyses, NIH 3T3 fibroblasts
were transfected with 2 mg of cognate mammalian expression vector
pAX142, pAX142 DN-186 Vav, or pAX142 DN-191 Vav2 using the Li-
pofectAMINE Plus (Life Technologies, Inc.) reagent according to man-
ufacturer’s instructions. 24 h after transfection, cells were trypsinized
and plated on 10 mg/ml fibronectin-coated glass coverslips (Carolina
Biologicals) and allowed to attach and spread for 2 h.
Transient Expression Reporter Gene Assays—NIH 3T3 cells were
transfected by calcium phosphate co-precipitation as described previ-
ously (32). 48 h after transfection, cells were starved for 15 h with
Dulbecco’s modified Eagle medium supplemented with 0.5% bovine calf
serum to reduce the level of serum activation of c-Jun. Analyses of the
cell lysates of the transiently transfected NIH 3T3 cells were performed
using enhanced chemiluminescence reagents and a Monolight 2010
luminometer (Analytical Luminescence) as described previously (33,
34). The reporter constructs utilized were previously described; Gal4-
Jun encodes the Gal4 DNA-binding domain fused to the NH2-terminal
transactivation domain of c-Jun (35), and 5xGal4-Luc contains the
luciferase gene under control of tandem copies of the Gal4 DNA-binding
sequences and the minimal promoter of c-fos.
Guanine Nucleotide Exchange Assays—cDNA fragments encoding
either the human Vav2 DH domain (residues 191–402) or the tandem
DH/PH/CRD (residues 191–573) were generated by polymerase chain
reaction and inserted into the NcoI/XhoI sites of the bacterial expres-
sion vector pET-28a (Novagen). The bacterial expression constructs
were transformed into the Escherichia coli strain BL21 (DE3), and
protein expression was induced with 1 mM IPTG at 25 °C. The recom-
binant proteins were His6-tagged at its COOH terminus and were
purified from bacterial lysate on a nickel-nitrilotriacetic acid agarose
column (Qiagen). The Vav2 DH protein was further purified on a S-200
size exclusion column (Amersham Pharmacia Biotech) and a source-Q
anion exchange column (Amersham Pharmacia Biotech). A similar bac-
terial expression vector encoding the isolated DH domain of Dbs has
been previously described (20). Bacterially expressed Tiam1 DH/PH
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protein was kindly provided by J. Sondek. Bacterially expressed GST-
RhoA(F25N), GST-Rac1(WT), and GST-Cdc42(WT) were expressed and
purified essentially as described (36). Bacterially expressed Ha-Ras
(1–166) was purified as described previously (37).
The GDP dissociation assays were carried out by the filter binding
method that was described previously (38). To prepare [3H]GDP-loaded
GST-Rho, GST-Rac, or GST-Cdc42, solutions containing 10 mM HEPES,
pH 7.5, 100 mM NaCl, 7.5 mM EDTA, 15 mM GDP, 5.5 mM [3H]GDP, and
12.5 mM of the GTPase were incubated for 25 min at 20 °C. The
[3H]GDP-bound GTPases were then stabilized by supplementing the
solution with 20 mM MgCl2. Nucleotide exchange reactions were per-
formed at 20 °C by diluting the [3H]GDP-loaded GST-RhoA, GST-Rac1,
or GST-Cdc42 to 4 mM in reaction mixtures containing either 4 mM GEF
(Vav2 DH, Dbs DH, Tiam1 DH/PH) or no GEF, 10 mM HEPES, pH 7.5,
5 mM MgCl2, 100 mM NaCl, 1 mM dithiothreitol, 50 mg/ml bovine serum
albumin, and 100 mM GTP (final concentrations). 30 ml of each reaction
mixture were sampled at 0, 5, 10, and 20 min and quenched in 1 ml of
ice-cold dilution buffer containing 20 mM Tris, pH 7.5, 100 mM NaCl,
and 20 mM MgCl2. The amount of [
3H]GDP remaining bound to the
GTPases was measured by filtering the quenched samples over nitro-
cellulose followed by scintillation counting. The percentage of [3H]GDP
remaining bound at each time point for the GEF catalyzed and uncata-
lyzed reactions were evaluated relative to time 0 of the uncatalyzed
reaction. Dbs DH and Tiam1 DH/PH were included as positive controls
for GST-Cdc42 and GST-Rac1, respectively. Results are the average of
two independent assays.
Fluorescence spectroscopic analysis of N-methylanthraniloyl (mant)-
GDP incorporation into GDP-preloaded GST-Rac1, GST-Cdc42, GST-
RhoA, or Ha-Ras was carried out using a Perkin-Elmer LS 50 B Spec-
trometer at 20 °C similar to as described previously (39). Exchange
reaction assay mixtures containing 20 mM Tris, pH 7.5, 50 mM NaCl, 10
mM MgCl2, 1 mM dithiothreitol, 50 mg/ml bovine serum albumin, 1%
glycerol, 400 nM mant-GDP (Biomol), and 2 mM of GTPase were pre-
pared and allowed to equilibrate with continuous stirring. After equil-
ibration, the Vav2 DH/PH/CRD polypeptide was added to 50 nM, and
the relative mant fluorescence (lex 5 360 hm, lem 5 440 hm) was
monitored. Experiments were performed in duplicate.
Immunofluorescence Analyses—NIH 3T3 fibroblasts were essentially
processed for immunofluorescence as described previously (40). Briefly,
cells were fixed in 3.7% formaldehyde in phosphate-buffered saline for
10 min, rinsed in Tris-buffered saline at pH 7.6 for 3 min, and perme-
abilized for 6 min in Tris-buffered saline containing 0.5% Triton X-100.
Expression of the DNA constructs was determined by staining with
mouse anti-Vav1 antibody (Upstate Technology, Lake Placid, NY) or
rabbit anti-Vav2 antibody generated against the COOH-terminal of
Vav22 followed by secondary antibodies conjugated to fluorescein iso-
thiocynate or Texas Red (Chemicon). Actin was visualized with Texas
Red-labeled phalloidin (Molecular Probes). Images were acquired
through a Micromax 5 MHz cooled CCD camera (Princeton Instrument)
on an Axiophot (Zeiss) microscope.
RESULTS
Vav2 Demonstrates GEF Exchange Activity on RhoA, Rac1,
and Cdc42 in Vitro—The Vav and Vav2 DH domains share
strong sequence identity (51%) (24, 25) (Fig. 1). Furthermore,
our sequence alignment and dendrogram analyses of DH do-
mains showed that related DH domains shared similar sub-
strate specificity (2). Therefore, the recent report that Vav2
showed distinct GEF activities from Vav was unexpected (18).
To further evaluate the activity of the DH domain of Vav2,
we constructed, expressed, and purified a bacterially expressed
hexahistidine-tagged DH domain fragment of Vav2 (residues
191–401) and analyzed the effect of this protein on the incor-
poration of cold GTP into [3H]GDP-loaded RhoA, Rac1, or
Cdc42 (Fig. 2). RhoA, Rac1, or Cdc42 alone did not exhibit
significant intrinsic GDP dissociation. However, the Vav2 DH
domain stimulated rapid and complete GDP dissociation from
RhoA, Rac1, and Cdc42 within ;20 min. In fact, the reaction
went to completion in 5 min with both Rac1 and Cdc42,
whereas only 25% of the [3H]GDP was released from RhoA
after the same time period. These assays were performed at
both stoichiometric and substoichiometric conditions (data not
shown). Furthermore, as controls, we examined the in vitro
GEF exchange activities of Dbl family members Dbs (DH do-
main) and Tiam-1 (DH/PH domain) on their respective GT-
Pases, Cdc42 and Rac1 (14, 20). We found that Vav2 had
similar exchange activities on Rac1 and Cdc42, as did Tiam-1
and Dbs, respectively. Finally, unlike proto-Vav and onco-Vav
(deletion of residues 1–67), which require phosphorylation for
efficient GEF activity in vitro (15, 16), the catalytic activity of the
isolated DH domain of Vav2 was not only more efficient than
previously observed for Vav but was also phosphorylation-inde-
pendent. Therefore, in our assays, we found that Vav2, like Vav,
displayed in vitro substrate specificities toward RhoA, Rac1, and
Cdc42. Moreover, we found that Vav2 displayed comparable
activity for Rac1 and Cdc42 and lower activity for RhoA.
2 K. Abe, K. L. Rossman, B. Liu, K. D. Ritola, D. Chiang, S. L. Campbell, K. Burridge, and C. J. Der, manuscript in preparation.
FIG. 1. Domain structure and se-
quence comparisons of the full-
length and NH2-terminal truncated
versions of Vav and Vav2. A, the do-
main structure of the full-length versions
of Vav and Vav2 are shown. CH, calponin
homology domain; AD, acidic domain; SR,
serine-rich region. The serine-rich region
is not present in Vav. The NH2-terminal
truncated and transforming versions of
each protein are shown directly below.
Both NH2-terminal truncated Vav and
Vav2 lack the entire calponin homology
and acidic domain regions. B, percentage
of amino acid sequence identity and sim-
ilarity between Vav and Vav2 generated
using the Boxshade program.
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Because sequences flanking the DH domain may influence
DH domain substrate specificity, we also evaluated the activity
of a bacterially expressed fragment of Vav2 that contains the
DH domain together with the COOH-terminal PH and cys-
teine-rich domains (designated DH/PH/CRD). We have found
that the equivalent version of Vav (DH/PH/CRD) is functional
in vivo for signaling and transforming activity (48). For these
analyses we employed a fluorescence spectroscopic analysis of
mant-GDP incorporation into GDP-preloaded Rac1, Cdc42,
RhoA, and Ha-Ras bacterially expressed proteins (Fig. 3). Sim-
ilar to our observations with the DH domain alone, we found
that the DH/PH/CRD polypeptide displayed comparable activ-
ity for Rac1 and Cdc42, lower activity for RhoA, and no activity
for Ha-Ras. Thus, the addition of flanking COOH-terminal
sequences required for Vav DH domain activity in vivo did not
alter the GTPase specificity of the Vav2 DH domain.
Vav and Vav2 Cause Indistinguishable Transformed Pheno-
types in NIH 3T3 Cells—In contrast to previous analyses (18),
our in vitro analyses showed that Vav2 does act as a GEF for
Rac1 and Cdc42, as well as RhoA, in vitro. The previous study
also found that Vav and Vav2 caused distinct transformed
phenotypes when expressed in NIH 3T3 cells (18, 25). For
example, whereas Vav caused the appearance of foci of trans-
formed cells that consisted of piled up, nonrefractile cells, Vav2
was reported to cause the appearance of foci that contained
multinucleated cells that included rounded and refractile cells.
This was consistent with their observed differences in Vav and
Vav2 substrate specificity. However, because our analyses
showed that Vav and Vav2 displayed the same substrate spec-
ificity, we next determined whether Vav and Vav2 caused
similar or distinct transformation phenotypes.
For these analyses, we used an NH2-terminal truncated mu-
tant of mouse Vav, DN-186 Vav, which lacks NH2-terminal
residues 1–186 (Fig. 1). We recently showed that this mutant of
Vav is several 100-fold more potent in focus-forming activity
when compared with the originally cloned onco-Vav (deletion of
residues 1–67) (27). We also generated an equivalent version of
human Vav2 by deleting residues 1–191 from its NH2 terminus
(designated DN-191 Vav2) (Fig. 1). Thus, both these mutants
lack the entire NH2-terminal sequences upstream of the DH
domain. A similar truncation mutant of Vav2 lacking residues
1–184 was shown previously to transform NIH 3T3 cells (25).
Like DN-186 Vav, DN-191 Vav2 showed potent focus-forming
activity when transfected into NIH 3T3 cells (;40 foci/mg of
DNA). The transformed foci caused by DN-191 Vav2 were in-
distinguishable in appearance from those caused by DN-186
Vav and consisted of dense clusters of nonrefractile cells (Fig.
4A). These foci were similar to those caused by activated forms
of RhoA or Rac1 but very distinct from those caused by acti-
vated Ras or by activated serine/threonine or tyrosine kinases
(not shown). We observed no multi-nucleated giant cells for
either the Vav- or Vav2-induced foci.
We then compared the morphology of NIH 3T3 cells stably
expressing activated Vav or Vav2. Both caused equivalent con-
sequences on cellular morphology (Fig. 4B). DN-186 Vav- and
DN-191 Vav2-transformed cells exhibited a nonrefractile,
strongly adherent appearance that was slightly more elongated
than the vector-transfected, untransformed NIH 3T3 cells. We
also plated NIH 3T3 cells that stably expressed Vav or Vav2
onto soft agar and examined their ability to grow in an anchor-
age-independent manner (Fig. 4C). We found that similar to
cells expressing activated Vav activated Vav2-expressing cells
formed colonies in soft agar. Thus, consistent with our data
showing similar GEF activities, we observed that activated Vav
and Vav2 caused qualitatively and quantitatively similar
transformed phenotypes when expressed in NIH 3T3.
Vav2 Transforming Activity Requires RhoA, Rac1, and
Cdc42—We recently showed that Vav transformation of NIH
3T3 cells required the activity of RhoA, Rac1, and Cdc42 (27).
Therefore, to assess the importance of RhoA, Rac1, and Cdc42
function in Vav2 transforming activity, we performed similar
experiments using DN-191 Vav2 using various approaches to
inhibit the function of Rho family GTPases.
We co-transfected DN-191 Vav2 with expression vectors en-
coding dominant negative mutants RhoA(19N), Rac1(17N), or
Cdc42(17N). By analogy to the Ras(17N) dominant negative
protein, these dominant negative mutants have been proposed
to inhibit Rho family protein function by forming nonproduc-
tive interactions with Dbl family members that associate with
the Rho GTPase substrate (41–43). We and others have used
these mutants to characterize the involvement of specific Rho
family GTPases in transformation by various Dbl family pro-
teins (12, 20, 44). Co-expression of dominant negative
RhoA(19N), Rac1(17N), or Cdc42(17N) caused significant re-
ductions, ranging from 65 to 90%, in Vav2 focus-forming activ-
ity (Fig. 5A).
We also used other approaches to support the inhibition of
Vav2 transformation that we observed with the dominant neg-
ative Rho GTPase mutants. We co-transfected DN-191 Vav2
with p190 Rho GAP, a protein that stimulates the intrinsic
GTP hydrolysis rate of RhoA (45), as a second approach to
evaluate an involvement of RhoA in Vav2 transformation. We
also co-transfected DN-191 Vav2 with a plasmid encoding the
C3 botulinum toxin, which specifically inhibits RhoA, RhoB,
and RhoC (but not Rac1 or Cdc42) function (Fig. 5B), or with a
plasmid encoding the isolated Cdc42 binding domain of WASP,
FIG. 2. Stimulation of GDP dissociation from Cdc42, Rac1, and RhoA from Vav2. Time course study for the dissociation of [3H]GDP from
the bacterially expressed GST-Rac1 (A), GST-Cdc42 (B), or GST-RhoA (C) in the presence of a bacterial expressed Vav2 DH domain fragment. A,
Tiam1 has been shown to specifically catalyze GTPase exchange activity on Rac1; hence, we used a bacterially expressed DH/PH domain fragment
of Tiam1 as a control to compare with Vav2 utilization of Rac1. We also used a bacterially expressed DH domain fragment of Dbs as a control (B)
that catalyzes GDP dissociation on Cdc42 (and RhoA). Experiments shown are representative of two independent assays that were performed in
duplicate. Symbols: A, l, Rac1; f, Vav2 1 Rac1; Œ, Tiam1 1 Rac1; B, l, Cdc42; f, Vav2 1 Cdc42; Œ, Dbs 1 Cdc42; C, RhoA; f, Vav2 1 RhoA.
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a Cdc42-specific effector (Fig. 5C). This WASP fragment has
been utilized as a specific inhibitor of Cdc42 function (10, 30,
31). Co-expression of p190 Rho GAP or C3 decreased Vav2
transforming activity by 90% (Fig. 5, A and B), whereas co-
transfection with the WASP fragment decreased Vav2 trans-
forming activity by 50% (Fig. 4C). Taken together with the data
from the use of dominant negative GTPases, our observations
support a role for RhoA, Rac1, and Cdc42 in mediating Vav2
transforming activity.
Vav2 Stimulates c-Jun Transcriptional Activity—Vav has
been shown to be a strong activator of the JNK mitogen-acti-
vated protein kinase and, consequently, the c-Jun transcription
factor (17, 46). In most cell types, JNK activity is stimulated by
activated Rac1 and Cdc42, but not RhoA (6, 7). Therefore, we
examined the ability of DN-191 Vav2 to stimulate c-Jun tran-
scriptional activity. For these studies, we performed transient
transcriptional assays in NIH 3T3 cells. We transfected cog-
nate empty vector or vectors encoding constitutively activated
RhoA(63L), Rac1(61L), or DN-191 Vav2 and assessed c-Jun
transcriptional activation (Fig. 6). In our assays, we found that
constitutively activated RhoA(63L) did not cause activation of
c-Jun, whereas both Rac(61L) and Vav2 caused over 3-fold
stimulation of c-Jun activity.
Vav2 Induces the Formation of Lamellipodia and Membrane
Ruffles—Previous studies found that Vav and Vav2 caused
distinct consequences on actin cytoskeletal organization when
stably expressed in NIH 3T3 cells (18). Whereas Vav caused a
disruption of stress fibers and a preferential localization of
actin to peripheral membrane structures, Vav2 induced the
formation of abundant stress fibers. In contrast, their analyses
of NIH 3T3 cells transiently expressing Vav or Vav2 showed
equivalent consequences, with both causing an induction of
lamellipodia and membrane ruffling and no obvious formation
of filopodia or stress fibers. However, this activity was distinct
from the significantly larger lamellipodia caused by activated
Rac1.
For our analyses, we transiently transfected NIH 3T3 cells
with DN-186 Vav, DN-191 Vav2, or their respective cognate
vectors. Cells expressing activated Vav or Vav2 displayed the
same consequences on actin organization (Fig. 7) as activated
Rac1 (not shown). When compared with empty vector-trans-
fected NIH 3T3 cells, cells expressing activated Vav or Vav2
were more rounded and displayed lamellipodia and membrane
ruffling, indicating that both are activators of Rac1 in vivo. In
contrast to previous observations (18), we did not see a disrup-
tion of actin stress fibers by activated Vav. Instead, both acti-
vated Vav- and Vav2-expressing cells retained well developed
actin stress fibers that were similar to those seen in untrans-
formed NIH 3T3 cells.
Our observations that Vav2 caused the induction of lamelli-
podia and membrane ruffling and that dominant negative Rac1
could block Vav2 transforming activity supported the possibil-
ity that Vav2 transformation is associated with constitutive
up-regulation of Rac1 function. To address this possibility, we
utilized a GST fusion protein containing the Cdc42/Rac binding
domain of PAK1 (residues 67–150) as an affinity reagent in a
pull-down assay to determine the level of GTP-bound Rac in
Vav2-transformed NIH 3T3 cells (47–49). The PAK serine/
threonine kinase is an effector of both Rac and Cdc42 and binds
preferentially to the active, GTP-bound forms of these two
GTPases. When compared with untransformed NIH 3T3 cells,
we found a 2.26-fold increase in Rac-GTP levels in Vav2-trans-
formed cells (Fig. 8). Thus, consistent with our in vitro GEF
analyses, Vav2 causes constitutive up-regulation of Rac
activity.
DISCUSSION
Although the precise sequence requirements that dictate the
GTPase specificity of DH domains remains to be delineated,
our sequence alignment analyses of DH domain sequences
showed a general relationship between sequence similarity and
substrate utilization (2). Therefore, it was unexpected that Vav
and Vav2, which share strong sequence identity in their DH
domains, would possess GEF activity for distinct GTPase tar-
gets. Furthermore, it was found that activated Vav2 caused
changes in cell morphology and actin cytoskeletal organization
and a transformed phenotype that were distinct from those
caused by activated Vav (18, 25). In contrast to these observa-
tions, we found that Vav and Vav2 share overlapping activities
and that both can act as GEFs for RhoA, Rac1, and Cdc42.
FIG. 3. Stimulation of mant-GDP in-
corporation into Rac1, Cdc42, RhoA,
and Ha-Ras by the Vav2 DH/PH/CRD
in vitro. The ability of bacterially ex-
pressed Vav2 DH/PH/CRD (50 nM) to
stimulate the incorporation of mant-GDP
into bacterially expressed GTPases (2 mM)
was measured by fluorescence spectros-
copy (lex 5 360 nm, lem 5 440 nm). A,
lower curve, GST-Rac1; upper curve, GST-
Rac1 1 DH/PH/CRD; B, lower curve,
GST-Cdc42; upper curve, GST-Cdc42 1
DH/PH/CRD; C, lower curve, GST-RhoA;
upper curve, GST-RhoA 1 DH/PH/CRD;
D, lower curve, Ha-Ras 1 DH/PH/CRD;
upper curve, Ha-Ras. Arrows indicate the
time point at which the Vav2 DH/PH/
CRD polypeptide was added to the ex-
change reaction mixture. Results are rep-
resentative of two independent assays.
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FIG. 4. Vav and Vav2 cause similar
transformed phenotypes in NIH 3T3
cells. A, foci of transformed cells induced
by DN-186 Vav and DN-191 Vav2. NIH
3T3 cells were transfected using the
pAX142 mammalian expression plasmid
(1 mg) or pAX142 encoding DN-186 Vav
(30 ng) and DN-191 Vav2 (1 mg). Photo-
graphs of foci were taken 14 days after
transfection. B, morphology of cells stably
expressing DN-186 Vav or DN-191 Vav2.
NIH 3T3 cells stably transfected cells ex-
pressing activated Vav or Vav2 were es-
tablished by pooling together multiple
drug-resistant colonies (.100) after
growth in medium supplemented with hy-
gromycin or geneticin selection. C, Vav-
and Vav2-transformed cells proliferate in
the absence of anchorage. NIH 3T3 cells
stably expressing activated Vav or Vav2
selected cells were seeded at 2 3 106 cells/
60-mm dish in growth medium containing
0.3% agar (over a 0.6% agar base layer)
for 10 days. Photographs were taken at 10
days.
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First, we found that bacterially expressed fragments of the
isolated DH or DH/PH/CRD domains of Vav2 exhibited GEF
activity for RhoA, Rac1, and Cdc42 in vitro. Second, NH2-
terminal truncated Vav2 caused the appearance of foci of trans-
formed cells that were similar to those induced by NH2-termi-
nal truncated and activated Vav. Vav- and Vav2-transformed
NIH 3T3 cells were similar in morphologic appearance on plas-
tic, and both displayed similar abilities to proliferate in soft
agar. Third, we showed that Vav2 transforming activity was
reduced by co-expression of various inhibitors of Rac1, RhoA,
and Cdc42. Fourth, like Vav, Vav2 also activated c-Jun, a
downstream target of the JNK mitogen-activated protein ki-
nase. Rac1 and Cdc42, but not RhoA, are activators of JNK in
NIH 3T3 cells. Fifth, like Rac1, we also found that Vav2 could
induce the formation of lamellipodia and membrane ruffles.
Finally, we determined that Rac-GTP levels were constitu-
tively up-regulated in Vav2-transformed cells. Thus, taken to-
gether, our data strongly suggest that Vav and Vav2 are acti-
vators of multiple, shared Rho family proteins.
Because Vav and Vav2 showed the most related sequence
relationship with each other in their DH domain sequences (2),
we had anticipated that Vav and Vav2 would share similar, if
not identical, GTPase targets for their GEF functions. During
the course of our studies, Bustelo and colleagues (18) showed
that Vav2 was an activator of RhoA, RhoB, and RhoG but not
Rac1 or Cdc42 in vitro. In contrast, we found that Vav2 exhib-
ited strong GEF activity for Rac1 and Cdc42, as well as for
RhoA. Possible explanations for the different results between
our group and Bustelo and colleagues may be the distinct types
of Vav2 constructs utilized in the assays as well as the fact that
we used human rather than mouse Vav2. For their in vitro
GEF exchange assays, Bustelo and colleagues used insect cell-
expressed, poly-histidine-tagged versions of either full-length
or NH2-terminal truncated and activated Vav2. In contrast, we
employed bacterially expressed versions of the isolated DH or
DH/PH/CRD domains of Vav2. Thus, it is possible that COOH-
terminal sequences, such as the SH3 and SH2 domains, may
influence the GTPase substrate specificity of the DH domain.
FIG. 5. Dominant negative RhoA,
Rac1, and Cdc42 block Vav2 focus-
forming activity. A, NIH 3T3 cells were
transfected both with the pAX142 and the
pZIP-NeoSV(x)1 mammalian expression
vectors and with the pAX-DN-191 Vav2 (2
mg) together with pZIP-NeoSV(x)1 (2 mg)
or pZIP-NeoSV(x)1 constructs encoding
the wild-type or dominant negative mu-
tants of RhoA (2 mg), Rac1 (2 mg), or
Cdc42 (2 mg), and Rho GAP p190 (2 mg).
B, the C3 exoenzyme inhibits Vav2 trans-
forming activity. NIH 3T3 cells were
transfected with pCDNA3 (2 mg) and
pAX142 vectors and with DN-191 Vav2 (2
mg) together with pCMV-C3 (2 mg). C, the
WASP-GBD blocks Vav2 transforming ac-
tivity. NIH 3T3 cells were transfected
with the pyDF30 (2 mg) and pAX142 vec-
tors and DN-191 Vav2 (2 mg) with pyDF30
(2 mg) or pyDF30 WASP-GBD (2 mg). Data
shown are representative of at least three
independent assays.
FIG. 6. Vav2 activates c-Jun transcriptional activity. NIH 3T3
cells were transiently transfected with the cognate empty pAX142
mammalian expression vector and pAX142 plasmids encoding the con-
stitutively activated Rho(63L) (500 ng/dish), Rac1(61L) and DN-191
Vav2, together with Gal4-Jun (250 ng/dish) and Gal4-Luc (2.5 mg/dish).
Data shown are representative of three independent assays.
FIG. 7. Both Vav and Vav2 induce the formation of lamellipo-
dia and membrane ruffling in NIH 3T3 cells. NIH 3T3 cells were
transfected with DN-186 Vav or DN-191 Vav2 and were analyzed by
indirect immunofluorescence for changes in the actin cytoskeleton. An
anti-Vav antibody (Santa Cruz Biotech) and an anti-Vav2 antibody
were used to detect Vav or Vav2 expression. Lamellipodia induction and
membrane ruffling were visualized using Texas Red-labeled phalloidin
antibodies. Data shown are representative of three independent
experiments.
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However, Bustelo and colleagues, as well as our unpublished
observations, showed that the SH domains were dispensable
for Vav function in vivo. This would argue that the COOH-
terminal SH2/SH3 domains do not play a significant role in
dictating the substrate specificity of Vav and Vav2. Finally,
changes in Rho GTPase substrate specificity may arise as a
result of the different methods of protein expression (E. coli
versus Sf9 cells) utilized that may result in distinct protein
modifications.
In addition to differences in GTPase substrates, Bustelo and
colleagues also found that Vav and Vav2 caused distinct trans-
formed phenotypes, as well distinct changes in cellular mor-
phology and actin cytoskeletal organization, when expressed in
NIH 3T3 cells. However, in our transformation, signaling, and
actin organization analyses, we found that NH2-terminal trun-
cated versions of Vav and Vav2 caused essentially indistin-
guishable consequences. Furthermore, we found that like Vav,3
Vav2 transforming activity was also dependent on the function
of Rac1, RhoA, and Cdc42. Our signaling and actin cytoskeletal
analyses also supported the possibility that Vav2 was an acti-
vator of Rac1 and/or Cdc42 in vivo. Like activated Rac1, Vav2
induced membrane ruffling and activation of JNK. Our cell-
based analyses employed an activated version of Vav2 that
retained all COOH-terminal sequences and was essentially
identical to the one used in the previous study. Thus, we believe
that our in vitro exchange results using the isolated DH or
DH/PH/CRD domains of Vav2 do accurately reflect the GTPase
specificity of authentic Vav2 in vivo. Therefore, we conclude
that Vav and Vav2 are activators of overlapping and multiple
small GTPases. At present, we do not have a clear explanation
for why our conclusions contrast those described previously,
except that our expression constructs, NIH 3T3 cell line (UNC
strain), and assay conditions were not identical to those em-
ployed in their studies. In particular, we have found that dif-
ferent strains of NIH 3T3 cells respond differently to the same
transforming protein (28).
Vav is activated in response to a very diverse spectrum of
extracellular stimuli in a variety of hematopoietic cell types
(50). These stimuli include growth factors, cytokines, interleu-
kins, and matrix components. At least some of these stimuli are
believed to activate Vav by phosphorylation of an NH2-termi-
nal tyrosine residue (Tyr174) (15), and this residue is also pres-
ent in Vav2. Thus, it is likely that Vav2 will be activated by an
equally diverse spectrum of extracellular stimuli in nonhema-
topoietic cells. Once activated, Vav and Vav2 are likely to
mediate the same repertoire of downstream signaling events
via activation of multiple small GTPases.
Like Vav, NH2-terminal truncation of the calponin homology
and acidic domains results in conversion of Vav2 to a potent
transforming protein. These two regions show strong sequence
identity in Vav and Vav2 and are likely to contribute similarly
to protein function. Although the exact mechanism by which
the NH2-terminal sequences of Vav serve to negatively regu-
late function remains to be delineated, our recent analyses
suggest that the NH2 terminus may facilitate an intramolecu-
lar interaction with COOH-terminal sequences and modulate
Vav membrane association (27). Whether the NH2-terminal
sequences of Vav2 also serves an analogous function will be
interesting to determine.
Vav and Vav2 share a similar array of COOH-terminal pro-
tein-protein or protein-lipid interaction domains. Following the
PH domain is a cysteine-rich domain and tandem SH3 domains
that flank a single SH2 domain. We recently found that dele-
tion of the SH3/SH2/SH3 domains of activated Vav did not alter
its transforming potential.3 Thus, although a significant num-
ber of binding components have been identified that associate
with these domains, these interactions are dispensable for Vav
and Vav2 transformation. Vav and Vav2 do diverge in their
COOH termini. Our sequence analyses identified a serine-rich
region located within the Vav2 COOH terminus, after the SH2
domain (Fig. 1). This region (residues 769–811) is not present
in Vav and comprises over 30% serine residues. This region
also contains a consensus tyrosine phosphorylation site. Thus,
further studies need to be performed to determine whether this
region endows Vav2 with functional differences from those
ascribed to Vav.
In summary, we have determined that like Vav, Vav2 is an
activator of Rac1, RhoA, and Cdc42. Whether these two highly
related Dbl family proteins serve the same functions in differ-
ent cell types will require further elucidation of the extracellu-
lar signals that cause Vav2 activation. Additionally, although it
is clear that Vav and Vav2 are activators of common small
GTPases, whether they are distinct in their abilities to activate
other Rho family proteins will be important to establish.
Acknowledgments—We thank Daniel Broek, Jeffrey Settleman, and
Robert Weinberg for providing cDNA constructs sequence, Jennifer
Parrish, and Misha Rand for preparation of figures and manuscript,
and Carol Martin, Que Lambert, and Kelley Rogers-Graham for tech-
nical assistance.
REFERENCES
1. Cerione, R. A., and Zheng, Y. (1996) Curr. Opin. Cell Biol. 8, 216–222
2. Whitehead, I. P., Campbell, S., Rossman, K. L., and Der, C. J. (1997) Biochim.
Biophys. Acta 1332, F1–F23
3. Narumiya, S., Ishizaki, T., and Watanabe, N. (1997) FEBS Lett.410, 68–72
4. Van Aelst, L., and D’Souza-Schorey, C. (1997) Genes Dev. 11, 2295–2322
5. Zohn, I. M., Campbell, S. L., Khosravi-Far, R., Rossman, K. L., and Der, C. J.
(1998) Oncogene 17, 1415–1438
6. Minden, A., Lin, A., Claret, F.-X., Abo, A., and Karin, M. (1995) Cell 81,
1147–1157
7. Coso, O. A., Chiariello, M., Yu, J.-C., Teramoto, H., Crespo, P., Xu, N., Miki, T.,
and Gutkind, J. S. (1995) Cell 81, 1137–1146
8. Perona, R., Montaner, S., Saniger, L., Sánchez-Pérez, I., Bravo, R., and Lacal,
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